Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on VALIRX PLC. We currently have 36 research reports from 3 professional analysts.
|11Jan17 07:00||RNS||CLINICAL TRIAL UPDATE - Positive VAL201 Results|
|30Dec16 07:00||RNS||Yorkville CLN Conversion|
|08Dec16 07:00||RNS||European Patent Granted for Lead Compound VAL201|
|02Dec16 16:15||RNS||Convertible Loan Facility|
|01Dec16 07:00||RNS||ValiSeek Clinical Development Update|
|29Nov16 07:00||RNS||Quarterly Update on Clinical Developments|
|03Nov16 07:00||RNS||ValiSeek Clinical Development Update|
Frequency of research reports
Research reports on
12 Jan 17
"Those hoping the President-elect's first news conference would convey a more considered and expansive approach to his forthcoming period in office were left disappointed. The media, on the other hand, had a field day with his dismissal of claims that Russia holds compromising intelligence on him, clashes with reporters, comparing intelligence agencies to Nazis and admitting Mexico may not pay for the wall after all, while opening his new administration up to charges of nepotism and conflict of interest. The absence of any new detail regarding his planned fiscal stimulus knocked the US$ back, while his repeated determination to reform the bidding process to ensure drugs are bought on a more economical basis, possibly including new import tariffs while offering no guarantees on Obamacare, saw health-care stocks become the day's principal casualty. The Dow Jones swung 140 points high to low during the session, dipping into negative territory while Trump was speaking, before all three principal US indices closed with modest gains. This morning's Asian trading ended largely in the negative, with the Nikkei hurting the most due to the Yen's re-strengthening, while Chinese equities were weaker in the absence of any relaxation Trump's apparently hard line on trade with the US. With T-bills climbing somewhat on Wednesday following a successful US$20bn 10-year note auction, attention will likely revert to the Fed Chair, Janet Yellen, and any view she might details regarding building inflationary pressures, in a speech she is due to make this afternoon. Today the UK will see release of the Halifax House Price Index Regional Breakdown, while the EU is due to publish November Industrial Production figures and the US details Initial Jobless Claims. With the results season now underway, the UK will also see a number of corporates publishing earnings or trading updates, including Associated British Foods (ABF.L), AO World (AO..L), ASOS (ASC.L), Barrett Developments (BDEV.L), Debenhams (DEB.L), Dunelm (DNLM.L), JD Sports (JD..L), M&S (MKS.L), Moss Bross (MOSB.L), Mothercare (MTC.L) and Tesco (TSCO.L). Without significant lead from the overnight markets, London is expected to open just modestly weaker with the FTSE-100 seen down some 10 points in opening trade this morning, having hit a fresh all-time high yesterday and setting a record for the longest uninterrupted 12-day rise in its history. Traders will also be listening for additional detail regarding Shire's (SHP.L) reported US$350m settlement in this US against allegations it used kickbacks to promote a skin substitute product." - Barry Gibb, Research Analyst
09 Dec 16
"The ECB surprised market traders yesterday by tapering its huge bond-buying program from next April. Extending asset purchases, that were due to end in March 2017, out to December but cutting from €80bn down to €60bn each month while leaving benchmark rates unchanged, met a mixed reaction from investors. Any reduction in asset buying must be seen to risk the Eurozone's own 'taper tantrum' that was witnessed in the US back in 2013. ECB members nevertheless clearly remain sensitive to potential economic and political instability across its 19-nations following Italian voter's recent rejection of constitutional reforms and key elections that are looming in 2017. As these various outcomes becomes more predictable, the ECB will likely provide greater guidance regarding the prospective duration and trajectory of its QE, which suggests the next round of tapering will likely be seen either at the September or December meetings next year. The immediate outcome of the action, however, was for the Euro to spike upward hitting a 1-month high against the US$, although it quickly gave most of these gains back, while bond yields pushed higher, with Italy and Spain not surprisingly leading the sell off, although long-dated German bund yields also reached their highest level in almost 12 months. Much of this background noise went virtually unnoticed in the US, where the Dollar continued its unabated rise, Treasuries fell and equities gained, albeit modestly, across all principal indices, with traders now taking a hike in short-term rates at next week's FOMC meeting virtually for granted. The Nikkei was the principal mover in Asia, rising more than 1% as asset managers celebrated the ECB's decision to extend its asset purchases along with relative Yen weakness; equity markets elsewhere in the region put on minor gains, despite Chinese consumer inflation figures reportedly rising for a third straight month in November, leaving only the Hang Seng falling back into the red, primarily due to a sharp sell-off of casino and gambling-related shares after the South China Post reported a prospective halving of ATM withdrawal limits in Macau for Unionpay bank card holders, presumably as part of the mainland's effort to rein-in this run-away activity in its provinces. The UK this morning is expected to release its Trade Balance figures and Construction Output data along with the Bank of England's Attitudes Survey, while this afternoon the US releases Consumer Sentiment and Wholesale Trade numbers. UK corporates expected to release earnings or trading updates include Abbey (ABBY.L), John Laing (JLG.L), Photo-Me (PHTM.L), Plant Impact (PIM.L) and SThree (STHR.L). Mixed sentiment accordingly pervades London equities this morning, with the FTSE-100 seen opening just fractionally firmer with a rise of perhaps 5 points in early trade." - Barry Gibb, Research Analyst
02 Dec 16
"By late Sunday, we should have a good idea whether or not Italian Prime Minister, Matteo Renzi, will be stepping down. The polls suggest his constitutional referendum, which has effectively become a confidence vote on his premiership, will get a 'thumbs down'. No new election is actually required until February 2018, but any attempt to simply replace him with another technocrat leader could well see a public, suffering from implosion of their bad-debt laden banking system, 38% youth unemployment and an inability to stifle giant capital outflows, clamouring for a snap election. This, of course, would open the door for Bepe Grillo's Five Star Movement, whose denouncement of the Euro could, in turn, generate in a wave of similar populist referendum voting across other dissatisfied EU nations, with France's own presidential election, due to take place on 7th May, the headline this morning following Francois Hollande's overnight declaration that he has decided not to stand. The prospect of Eurozone's collapse, however, was not the driver of the US session, which started in the positive following release of strong November Manufacturing ISM data, but waned later as a sell-off amongst tech issues pushed the NASDAQ sharply down, while the Dow Jones managed to hold onto modest gains due to sustained switching into financials, as divergence between the two sectors and the rout in government bond markets since Trump's election continued. Asian shares were lower across the board, with the Nikkei suffering as the Yen found buyers amongst US$ sceptics waiting for flaws in the Trump rally to show through, which dragged the other regional markets with it. With investors now virtually taking a 25bp hike by the Fed later this month for granted, focus this afternoon is likely to centre on the important US employment report, with forecasts in the 180k to 200k range, taking unemployment to 4.8% with a modest rise in hourly earnings of around 0.1%. The UK will also report Construction PMI figures this morning while corporates due to disclose earnings or trading updates include 88 Energy (88E.L), Altona Energy (ANR.L) and Berkeley Group Holdings (BKG.L). Traders meanwhile continue to watch oil futures carefully; although prices moderated during the Asian session, sentiment following OPEC's agreement remains positive with January's light, sweet crude trading a whisker below US$51 on the Mercantile Exchange, as they weigh up expectations on the terms being upheld or the various participants instead deciding to cheat on quotas rather than give up market share to US shale producers. London equities opened in a nervous mood this morning, with the FTSE-100 down over 57 points in early trading." - Barry Gibb, Research Analyst
30 Nov 16
Oil is in focus today ahead of OPEC’s 171st ordinary meeting scheduled to open in Vienna at 11:00hrs local time, followed by the secretary-general holding a press conference at 16:00hrs. Crude prices weaken around 4% during yesterday’s European and US sessions, only to recover somewhat in the early hours of Wednesday after Iran and Iraq indicated a willingness to hold production levels steady as their contribution toward the Organisation’s proposal to trim output by 32.5m to 33.0m barrels per day. Still someway from Saudi Arabia’s own demand for a broadly-based cut in which all major contributors participate, and given that non-member, Russia, is expected to be absent, hopes of a successful outcome have faded somewhat. With Trump apparently set to appoint key supporter and Wall Street veteran, Steven Mnuchin, 53, as Treasury Secretary US equities rose fractionally across the board, with weakness in energy stocks, due to WTI plunging to a two-week low, compensated by a strong run in healthcare. Asia by comparison was mostly weaker, with only the US$-dominated Hang Seng remaining marginally positive, while the Shanghai Composite fell sharply away as traders again considered the potential impact of Trump’s proposed import tariffs on Chinese-made goods, as the Nikkei closed unchanged following marginally better October industrial output data and the ASX was pressured by a general sell-off amongst its oil stocks. Traders in Europe this morning will be examining the European Council President, Donald Tusk’s, response to a letter from UK MPs in which he stated that the EU cannot enter side-talks regarding the status if citizens until the UK actually triggers Article 50. This adds to the lack of Brexit transparency already fostered by Theresa May’s government and is considered to be behind the decline in GfK’s long-running consumer confidence index, which fell 5 points in November and now stand at 16 points below the level reached this time last year, albeit contrasting sharply with the positive UK mortgage data released yesterday which pushed the housebuilding sector up in the process. While OPEC takes centre stage, analysts will be pouring over the Bank of England’s stress test results this morning, with a particular focus on RBS as the most vulnerable of the majors, having factored in deep recessionary scenarios including a plunge in house prices, a halving of oil and a spike in unemployment. The FTSE is due to release its quarterly review and the Eurozone is also due to produce its flash inflation estimate. UK corporates expected to release earnings or trading updates include Biffa (BIFF.L), Brewin Dolphin (BRW.L), Britvic (BVIC.L), Greene King (GNK.L), RPC Group (RPC.L), Sage Group (SGE.L), Telford Homes (TEF.L) and Zoopla (ZPLA.L). The FTSE-100 is seen to be 5 points up in early trading.
Panmure Morning Note 15-02-2017
15 Feb 17
With the early January trading update having prompted us to upgrade forecasts, today’s interim results show how the group’s focus on areas such as product development and international sales are translating through to growth in both the top and bottom-line. The consistency of delivery is what impresses us, reflecting the maturity of the management team and the clarity of the longterm vision. We repeat our Buy recommendation.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume
Panmure Morning Note 20-02-2017
20 Feb 17
Chi-Med has announced the initiation of a Phase II study of savolitinib in locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) in China. This is a disease where patients are usually diagnosed by normal pathology (i.e. not via molecular diagnostics methods) but given that 20-30% of PSC patient show c-Met gene amplification this potentially represents a very rich patient pool for savolitinib as a highly selective and potent oral c-Met inhibitor. The continued strength of Chi-Med’s clinical momentum is further demonstrated by today’s news and we consider this represents further upside potential against our existing investment case. We repeat our Buy recommendation.
Capital increase to support accelerated growth
14 Feb 17
Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced over the last year to accelerate the rate of growth, including global commercial infrastructure and the development of a pipeline of finished medical devices. The company has announced a capital increase, as well as some strategic investor venture debt, to raise gross funds of up to £12.0m to fund these initiatives, with a target of generating a five-fold sales increase over 5 years and profitability in 2019.
Discovering a sustainable model
21 Feb 17
We expect C4XD to begin to deliver commercially in 2017, following the shift in strategy away from fee for service in 2016. Over the next 12 months we expect C4XD to sign its first pre-clinical out-licensing deal, develop at least one more product line and sign at least one more strategic alliance. We believe this demonstration of the model will translate to a step up in value and we initiate coverage with a BUY recommendation and 129p price target.